Adults who have a diagnosis of moderate to severe plaque psoriasis (plaque PsO) may qualify for this clinical research trial and receive investigational oral medication (JNJ-77242113 or Deucravacitinib) or placebo.
  • Age: ≥ 18 years old
  • BSA ≥ 10, PASI ≥ 12, IGA ≥ 3
  • Diagnosis of Plaque PsO within the past 6 months

Patients will be asked to visit the clinic about 24 times over approximately 165 weeks. There is no cost to participate, and participants will be reimbursed for their time and travel.

For further information on the study, please follow the link:

Study Details | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | ClinicalTrials.gov

Trial ID: NCT06143878


If you are interested and would like to participate in this trial, please register your details and answer a few short questions for our recruitment team to back to you: eligibility questionnaire

Book Appointment